Azienda Ospedaliera Di Padova Trials

Azienda Ospedaliera Di Padova	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cillo, Umberto

ORCHESTRA-4, NCT05222139: Monitoring COVID-19 Vaccination Response in Fragile Populations

Completed

N/A

8894

Europe, RoW

COVID-19 vaccination

University of Bologna, Universita di Verona, Hospital Universitario Virgen Macarena, Azienda Ospedaliera di Padova, Azienda Ospedaliero-Universitaria di Parma, Azienda Ulss 2 Marca Trevigiana, University College Dublin, Luxembourg Institute of Health, ICONA Foundation, University Medical Center Groningen, University of Buenos Aires, PENTA Foundation, Universiteit Antwerpen, Institut National de la Santé Et de la Recherche Médicale, France, Helmholtz Zentrum München, CINECA consorzio universitario italiano, Charite University, Berlin, Germany, Centre de Recherche Médicale de Lambaréné

SARS CoV 2 Infection, Vaccination; Infection, Breakthrough Infection

07/23

11/24

Tarantini, Giuseppe

NCT04280029: SELUTION SLR™ 014 In-stent Restenosis

Active, not recruiting

N/A

418

Europe, Canada, US, RoW

SELUTION SLR™ DEB, Control

M.A. Med Alliance S.A., Iqvia Pty Ltd, Cordis Corporation

Coronary Restenosis

07/25

08/29

NCT05844969: Circle Method Observational Project - Non-interventional, Retrospective, Multicenter Data Collection

Not yet recruiting

N/A

Europe

Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences

Aortic Stenosis With Bicuspid Valve

08/25

NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting

N/A

200

Europe

Incyte Biosciences Italy S.r.l, Advice Pharma Group srl

DLBCL - Diffuse Large B Cell Lymphoma

06/25

06/27

TARGET FIRST, NCT04753749 / 2020-005933-34: Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

Completed

N/A

2248

Europe

Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin), Standard DAPT

MicroPort CRM, European Cardiovascular Research Center

Myocardial Infarction, Acute, Coronary Artery Disease

05/25

VANTAGE, NCT04788888: Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

Recruiting

N/A

590

Europe, RoW

Navitor Transcatheter Aortic Valve and FlexNav Delivery System

Abbott Medical Devices

Symptomatic Severe Aortic Stenosis

06/25

02/36

NCT05601453: The ReTAVI Prospective Observational Registry

Recruiting

N/A

150

Europe, Canada, RoW

Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI, redo-TAVR, Valve-in-Valve (ViV), TAV-in-TAV, TAVR-in-TAVR, Revalve

Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences

Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure

09/25

12/26

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

Giannini, Sandro

XLHRegistry, NCT03193476: Registry for Patients With X-Linked Hypophosphatemia

Recruiting

N/A

1343

Europe, RoW

Kyowa Kirin Pharmaceutical Development Ltd, Iqvia Pty Ltd

X-Linked Hypophosphatemia

02/29

07/29

Matute, W Giron

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Martínez, JM Cifrian

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Ferguson, K

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Putla, S

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Wijsenbeek-Lourens, M

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Necki, M

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Molina-Molina, M

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Tulek, B

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Rijswijk, R van

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Damps-Konstanska, I

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cillo, Umberto

ORCHESTRA-4, NCT05222139: Monitoring COVID-19 Vaccination Response in Fragile Populations

Completed

N/A

8894

Europe, RoW

COVID-19 vaccination

SARS CoV 2 Infection, Vaccination; Infection, Breakthrough Infection

07/23

11/24

Tarantini, Giuseppe

NCT04280029: SELUTION SLR™ 014 In-stent Restenosis

Active, not recruiting

N/A

418

Europe, Canada, US, RoW

SELUTION SLR™ DEB, Control

M.A. Med Alliance S.A., Iqvia Pty Ltd, Cordis Corporation

Coronary Restenosis

07/25

08/29

NCT05844969: Circle Method Observational Project - Non-interventional, Retrospective, Multicenter Data Collection

Not yet recruiting

N/A

Europe

Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences

Aortic Stenosis With Bicuspid Valve

08/25

Recruiting

N/A

200

Europe

Incyte Biosciences Italy S.r.l, Advice Pharma Group srl

DLBCL - Diffuse Large B Cell Lymphoma

06/25

06/27

Completed

N/A

2248

Europe

Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin), Standard DAPT

MicroPort CRM, European Cardiovascular Research Center

Myocardial Infarction, Acute, Coronary Artery Disease

05/25

VANTAGE, NCT04788888: Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

Recruiting

N/A

590

Europe, RoW

Navitor Transcatheter Aortic Valve and FlexNav Delivery System

Abbott Medical Devices

Symptomatic Severe Aortic Stenosis

06/25

02/36

NCT05601453: The ReTAVI Prospective Observational Registry

Recruiting

N/A

150

Europe, Canada, RoW

Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI, redo-TAVR, Valve-in-Valve (ViV), TAV-in-TAV, TAVR-in-TAVR, Revalve

Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences

Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure

09/25

12/26

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

Giannini, Sandro

XLHRegistry, NCT03193476: Registry for Patients With X-Linked Hypophosphatemia

Recruiting

N/A

1343

Europe, RoW

Kyowa Kirin Pharmaceutical Development Ltd, Iqvia Pty Ltd

X-Linked Hypophosphatemia

02/29

07/29

Matute, W Giron

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Martínez, JM Cifrian

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Ferguson, K

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Putla, S

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Wijsenbeek-Lourens, M

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Necki, M

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Molina-Molina, M

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Tulek, B

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Rijswijk, R van

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25

Damps-Konstanska, I

CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting

160

Europe, Canada, RoW

nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg

Trevi Therapeutics

Idiopathic Pulmonary Fibrosis

04/25



	Diseases Companies Products Productz Mechanisms of Action Sites